Abstract Two major treatment strategies employed in non-small cell lung cancer, NSCLC, are tyrosine kinase inhibitors, TKIs, and immune checkpoint inhibitors, ICIs. The choice of strategy is based on heterogeneous biomarkers that can dynamically change during therapy. Thus, there is a compelling nee...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!